This April, the European Union (EU) prohibited selling new cosmetic products tested on animals without any exemptions (1). Accordingly, it is forbidden to place a new product on the market that containsevenonenewingredienttestedonanimalsinoroutoftheEU, even if the final product was not tested on animals (2). It is also wellknown that pharmaceutical drug development is extremely timeconsuming and expensive; moreover, about 90% of drugs fail after preclinical animal testing in human safety and efficacy trials. Additionally, in patients,~ 1/6 newly marketed drugs are withdrawn or discontinued due to serious adverse effects (eg, hepatic, cardiovascular, hematologic, neurologic, and carcinogenic)(3). Potentially beneficial drugs can also fail and never be placed on the marketifthesearecategorisedastoxicorineffectiveduringpreselection based on animal tests (eg, in recent conditions, aspirin could fail regarding its toxicity test results on rats and rhesus monkey embryos). Thus, certain patients could not benefit or even be omitted due to the limitations of animal models (4). Both US Food and Drug Administration (FDA) and European Medicine Agency (EMA) modernisation acts aim to replace and decrease animal testing. Therefore, the bioengineering research area has rapidly improved in the last decade. Moreover, in vitro human model systems have undergone enormous developments nowadays. In the last pandemic situation, the development of COVID vaccines showed that faster and more efficient technologies are necessary for crisis and medical developments, and we have to leap over animal experiments anduseclinicaltestsasfastaspossible (5). Growingevidencepropagates thosealternativetechnologies (relevanthumancell-based—eg, organon-chips or biofabricated models—or artificial intelligence-combined technologies) could help test and predict human response and toxicity in medical research more accurately (6, 7). In vitro disease model developments have great efforts to create and serve the need of reducing, and replacing animal experiments and establishing human cell-based in vitro test systems for research use, innovations, and drug tests. We know and accept the quote:“ALL models are wrong but some are useful”—(George EO Box, one of the greatest statisticians of the 20th century). We need human cell-based test systems for disease models and experimental cancer research; therefore, in vitro three-dimensional (3D) models have a renaissance, and the development of these technologies is growing ever faster.